Actinium-225 PSMA PLGA Nanoparticles for Prostate Cancer Therapy

A prospective quantitative experimental study details the development of a targeted alpha therapy delivery vehicle using PLGA-chitosan-folic acid nanoparticles. The dataset includes tables and summaries from experiments on radiolabeling, nanoparticle preparation, functionalization, drug encapsulation, and in-vitro release. It was authored by Yonwaba Mzizi and published on figshare in April 2026.

Use Cases

• Analyze radiochemical purity and labeling efficiency based on the described cut-and-count method using iTLC TSA strips.
• Model in-vitro drug release kinetics from PLGA-chitosan-folic acid nanoparticles.
• Compare nanoparticle preparation and functionalization protocols for targeted alpha therapy.
• Validate quality control methods for 225Ac-PSMA617-TFA radiopharmaceuticals.

Strengths

• Data is derived from a prospective quantitative experimental study, suggesting a structured research design.
• Includes results from multiple specific experiments, such as radiolabeling, nanoparticle preparation, and in-vitro drug release.
• Radiochemical purity was determined in triplicate, indicating a measure of methodological rigor.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The primary data format is PDF (4.1 MB), which may require extraction for computational analysis.

Provenance

Source

figshare

Collection Method

Prospective quantitative experimental study conducted by the author.

Freshness

Last updated 2026-04-16 10:02:08; freshness should be verified.